Matches in SemOpenAlex for { <https://semopenalex.org/work/W2958972283> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2958972283 abstract "<ns4:p><ns4:bold>Background:</ns4:bold> The Portfolio-To-Impact (P2I) P2I model is a recently developed product portfolio tool that enables users to estimate the funding needs to move a portfolio of candidate health products, such as vaccines and drugs, along the product development path from late stage preclinical to phase III clinical trials, as well as potential product launches over time. In this study we describe the use of this tool for analysing the vaccine portfolio of the European Vaccine Initiative (EVI). This portfolio includes vaccine candidates for various diseases of poverty and emerging infectious diseases at different stages of development.</ns4:p><ns4:p> <ns4:bold>Methods:</ns4:bold> Portfolio analyses were conducted using the existing assumptions integrated in the P2I tool, as well as modified assumptions for costs, cycle times, and probabilities of success based on EVI’s own internal data related to vaccine development.</ns4:p><ns4:p> <ns4:bold>Results:</ns4:bold> According to the P2I tool, the total estimated cost to move the 18 candidates currently in the EVI portfolio along the pipeline to launch would be about US $470 million, and there would be 0.69 expected launches across all six diseases in EVI’s portfolio combined during the period 2019-2031. Running of the model using EVI-internal parameters resulted in a significant increase in the expected product launches.</ns4:p><ns4:p> <ns4:bold>Conclusions:</ns4:bold> Not all the assumptions underlying the P2I tool could be tested in our study due to limited amount of data available. Nevertheless, we expect that the accelerated clinical testing of vaccines (and drugs) based on the use of controlled human infection models that are increasingly available, as well as the accelerated approval by regulatory authorities that exists for example for serious conditions, will speed up product development and result in significant cost reduction. Project findings as well as potential future modifications of the P2I tool are discussed with the aim to improve the underlying methodology of the P2I model.</ns4:p>" @default.
- W2958972283 created "2019-07-23" @default.
- W2958972283 creator A5009408576 @default.
- W2958972283 creator A5014383827 @default.
- W2958972283 creator A5021843777 @default.
- W2958972283 creator A5046458474 @default.
- W2958972283 creator A5060734571 @default.
- W2958972283 creator A5064946658 @default.
- W2958972283 creator A5072025129 @default.
- W2958972283 creator A5084382216 @default.
- W2958972283 date "2020-02-04" @default.
- W2958972283 modified "2023-10-15" @default.
- W2958972283 title "Pipeline analysis of a vaccine candidate portfolio for diseases of poverty using the Portfolio-To-Impact modelling tool" @default.
- W2958972283 cites W2123114485 @default.
- W2958972283 cites W2273267066 @default.
- W2958972283 cites W2402631208 @default.
- W2958972283 cites W2757294648 @default.
- W2958972283 cites W2770726641 @default.
- W2958972283 cites W2802767235 @default.
- W2958972283 cites W2809733585 @default.
- W2958972283 cites W4246921789 @default.
- W2958972283 doi "https://doi.org/10.12688/f1000research.19810.2" @default.
- W2958972283 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7043114" @default.
- W2958972283 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32148758" @default.
- W2958972283 hasPublicationYear "2020" @default.
- W2958972283 type Work @default.
- W2958972283 sameAs 2958972283 @default.
- W2958972283 citedByCount "3" @default.
- W2958972283 countsByYear W29589722832021 @default.
- W2958972283 crossrefType "journal-article" @default.
- W2958972283 hasAuthorship W2958972283A5009408576 @default.
- W2958972283 hasAuthorship W2958972283A5014383827 @default.
- W2958972283 hasAuthorship W2958972283A5021843777 @default.
- W2958972283 hasAuthorship W2958972283A5046458474 @default.
- W2958972283 hasAuthorship W2958972283A5060734571 @default.
- W2958972283 hasAuthorship W2958972283A5064946658 @default.
- W2958972283 hasAuthorship W2958972283A5072025129 @default.
- W2958972283 hasAuthorship W2958972283A5084382216 @default.
- W2958972283 hasBestOaLocation W29589722831 @default.
- W2958972283 hasConcept C10138342 @default.
- W2958972283 hasConcept C144133560 @default.
- W2958972283 hasConcept C2524010 @default.
- W2958972283 hasConcept C2780821815 @default.
- W2958972283 hasConcept C33923547 @default.
- W2958972283 hasConcept C90673727 @default.
- W2958972283 hasConceptScore W2958972283C10138342 @default.
- W2958972283 hasConceptScore W2958972283C144133560 @default.
- W2958972283 hasConceptScore W2958972283C2524010 @default.
- W2958972283 hasConceptScore W2958972283C2780821815 @default.
- W2958972283 hasConceptScore W2958972283C33923547 @default.
- W2958972283 hasConceptScore W2958972283C90673727 @default.
- W2958972283 hasLocation W29589722831 @default.
- W2958972283 hasLocation W29589722832 @default.
- W2958972283 hasLocation W29589722833 @default.
- W2958972283 hasLocation W29589722834 @default.
- W2958972283 hasOpenAccess W2958972283 @default.
- W2958972283 hasPrimaryLocation W29589722831 @default.
- W2958972283 hasRelatedWork W1968606986 @default.
- W2958972283 hasRelatedWork W1982395084 @default.
- W2958972283 hasRelatedWork W2001958646 @default.
- W2958972283 hasRelatedWork W2061420013 @default.
- W2958972283 hasRelatedWork W2144786369 @default.
- W2958972283 hasRelatedWork W2317370663 @default.
- W2958972283 hasRelatedWork W2345618447 @default.
- W2958972283 hasRelatedWork W2375526090 @default.
- W2958972283 hasRelatedWork W4230341657 @default.
- W2958972283 hasRelatedWork W2187979104 @default.
- W2958972283 isParatext "false" @default.
- W2958972283 isRetracted "false" @default.
- W2958972283 magId "2958972283" @default.
- W2958972283 workType "article" @default.